The Phase 3 PERSEUS trial (NCT04458051) investigating tolebrutinib for Primary Progressive Multiple Sclerosis (PPMS) reached primary completion on 2025-11-14. This significant milestone indicates that data collection for the primary endpoint has concluded, moving the study closer to potential results.
Background
Tolebrutinib is a Bruton's Tyrosine Kinase (BTK) inhibitor being investigated for neurological conditions. Primary Progressive Multiple Sclerosis (PPMS) is a chronic, debilitating neurological disease characterized by continuous worsening of neurological function from the onset, without early relapses or remissions. Current treatment options for PPMS are limited, highlighting the ongoing need for new therapeutic approaches to address disability progression.
Trial design
The PERSEUS study (NCT04458051), titled "Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)," is a Phase 3, randomized, placebo-controlled trial. It enrolled 767 participants diagnosed with Primary Progressive Multiple Sclerosis. The study's primary objective is to determine the efficacy of tolebrutinib (SAR442168) compared to placebo in delaying disability progression in PPMS. Secondary objectives include evaluating efficacy on clinical endpoints, magnetic resonance imaging (MRI) lesions, cognitive performance, physical function, and quality of life. The trial also aims to evaluate the safety and tolerability of tolebrutinib, as well as its population pharmacokinetics (PK) in PPMS and its relationship to efficacy and safety, and its pharmacodynamics. Interventions in the trial included tolebrutinib and placebo.
What this means
The primary completion of the PERSEUS trial marks a crucial step in the evaluation of tolebrutinib for Primary Progressive Multiple Sclerosis. This indicates that all participants have completed the study period necessary to assess the primary endpoint, and data analysis can now proceed. For patients with PPMS, the potential for a new treatment targeting disability progression represents a significant area of interest, given the limited therapeutic landscape. The completion of this Phase 3 study brings the scientific and medical communities closer to understanding tolebrutinib's potential role in managing this challenging condition.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04458051, titled "Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)," was posted on 2025-11-14 on clinicaltrials.gov.